Current Report Filing (8-k)

0001582249 false 0001582249 2021-11-22 2021-11-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 22, 2021

 

RASNA THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Nevada		333-191083		39-2080103
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

420 Lexington Avenue, Suite 2525, New York, NY		10170
(Address of principal executive offices)		(Zip Code)

 

Registrant’s telephone number, including area code: 646-396-4087

 

 

 

(Former name or former address, if changed since last report)

 

Copies to:

Jeffrey Fessler, Esq.

Sheppard, Mullin, Richter & Hampton LLP

30 Rockefeller Plaza

New York, New York 10112

Telephone: [phone]

Facsimile: [phone]

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered

  

 

 

 

 

 

Item 4.01 Change in Registrant’s Certifying Accountant

 

On November 29, 2021, Rasna Therapeutics, Inc. (the “Company”) dismissed Marcum LLP (“Marcum”) as the Company’s independent registered public accounting firm, effective immediately. On November 29, 2021, the Company appointed Mazars USA LLP (“Mazars”) as the Company’s new independent registered public accounting firm effective as of November 29, 2021.

 

The Audit Committee of the board of directors of the Company approved the dismissal of Marcum and the appointment of Mazars.

 

The reports of Marcum on the Company’s financial statements for each of fiscal years ended September 30, 2020 and 2019 did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principle.

 

During the fiscal years ended September 30, 2020 and 2019, and the subsequent interim period through November 29, 2021, there were no disagreements (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions) between the Company and Marcum on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures which disagreements, if not resolved to the satisfaction of Marcum would have caused Marcum to make reference thereto in their reports on the financial statements for such years. The Company disclosed in its Form 10-K for the fiscal year ended September 30, 2020 and in subsequent 10-Q interim period filings, that its internal control over financial reporting was not due to a lack of accounting resources and an ineffective control environment.

 

The Company provided Marcum with a copy of the disclosures it is making in this Current Report on Form 8-K and requested that Marcum furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements contained herein. A copy of Marcum’s letter, dated November 30, 2021 is filed as Exhibit 16.1 to this Current Report on Form 8-K.

 

During the fiscal year ended September 30, 2020 and the period from October 1, 2020 through November 29, 2021, neither the Company, nor anyone acting on its behalf, consulted with Mazars regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that may be rendered on the Company’s financial statements, and Mazars did not provide either a written report or oral advice to the Company that was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue, or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

 

 Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

 

Exhibit No.		Description
16.1		Letter from Marcum LLP dated November 30, 2021
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date:  November 30, 2021

 

	RASNA THERAPEUTICS, INC.
	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief FinancialOfficer

 

 

2